Raymond James Financial
PVLA

Raymond James Financial’s Palvella Therapeutics PVLA Stock Holding History

Raymond James Financial’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.62M Sell
23,663
-1,783
-7% -$216K ﹤0.01% 3005
2026
Q1 		$3.17M Buy
25,446
+3,182
+14% +$332K ﹤0.01% 2967
2025
Q4 		$2.33M Sell
22,264
-1,574
-7% -$134K ﹤0.01% 3145
2025
Q3 		$1.49M Buy
23,838
+23,833
+476,660% +$1.06M ﹤0.01% 3401
2025
Q2 		$113 Buy
+5
New +$117 ﹤0.01% 6836

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Raymond James Financial's PVLA Position: Q2 2026 in Review

Raymond James Financial reduced its Palvella Therapeutics (PVLA) stake by 7% in Q2 2026, selling an estimated $216K and leaving 23,663 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #3005.

Raymond James Financial first reported a position in PVLA in Q2 2025 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Raymond James Financial held 23,663 shares of Palvella Therapeutics worth $3.62M as of Q2 2026.
  • Raymond James Financial sold 1,783 Palvella Therapeutics shares in Q2 2026, an estimated $216K.
  • Palvella Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3005 holding.
  • Raymond James Financial first reported a position in Palvella Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.